The New England Journal of Medicine has publicized new clinical trial data of Moderna’s mRNA-1273 vaccine, reporting a high efficacy rate against COVID-19.
According to the data, which involved more than 30,000 participants, the vaccine demonstrated an efficacy rate of 94.1 percent against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain, in comparison to a placebo.
The clinical trial was conducted across countless sites within the United States, enrolling only adult participants with no prior infection of the viral disease. The vaccine was administered between late-July and late-October 2020.
An estimated 79 percent of the participants, or the majority, were white Americans, while 20 percent were Latino, and 10 percent were Black Americans.
Adverse reactions after receiving the vaccine were relatively mild, with only common symptoms such as headaches, muscle aches, and fatigue, present after the first and second dose.
All in all, Moderna’s mRNA-1273 vaccine, which received approval by the Food and Drug Administration, is a viable option to other available alternatives for combatting the virus.
The findings were published on December 30th, 2020.
